Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Wolinsky

Showing results (231-240 of 331) with videos related to

Pageof 34
Sort By:
Annals of Neurology|January 31, 2007
Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trialJerry S Wolinsky, Ponnada A Narayana, Paul O'Connor, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 11, 2016
Novel fMRI working memory paradigm accurately detects cognitive impairment in multiple sclerosisFlavia Nelson, Mohammad A Akhtar, Edward Zúñiga, et al.
Multiple Sclerosis and Related Disorders|November 17, 2017
Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 yearsFred D Lublin, Stacey S Cofield, Gary R Cutter, et al.
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|January 1, 1997
Clinical and magnetic resonance imaging changes correlate in a clinical trial monitoring cyclosporine therapy for multiple sclerosis. The MS Study GroupG J Zhao, D K Li, J S Wolinsky, et al.
Annals of Neurology|May 1, 1977
Adenine arabinoside in the treatment of progressive multifocal leukoencephalopathy: use of virus-containing cells in the urine to assess response to therapyK H Rand, K P Johnson, L J Rubinstein, et al.
Annals of Neurology|February 21, 2013
Randomized study combining interferon and glatiramer acetate in multiple sclerosisFred D Lublin, Stacey S Cofield, Gary R Cutter, et al.
Journal of Magnetic Resonance Imaging : JMRI|November 26, 2013
Contrast enhanced MR venography with gadofosveset trisodium: evaluation of the intracranial and extracranial venous systemLarry A Kramer, Alan M Cohen, Khader M Hasan, et al.
Neurology|September 3, 2021
Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple SclerosisStephen L Hauser, Ludwig Kappos, Xavier Montalban, et al.
JAMA Neurology|June 9, 2020
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical TrialsLudwig Kappos, Jerry S Wolinsky, Gavin Giovannoni, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 12, 2021
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trialBianca Weinstock-Guttman, Robert Bermel, Gary Cutter, et al.
Pageof 34

Showing results (231-240 of 331) with videos related to

Sort By:
Pageof 34
Annals of Neurology|January 31, 2007
Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trialJerry S Wolinsky, Ponnada A Narayana, Paul O'Connor, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 11, 2016
Novel fMRI working memory paradigm accurately detects cognitive impairment in multiple sclerosisFlavia Nelson, Mohammad A Akhtar, Edward Zúñiga, et al.
Multiple Sclerosis and Related Disorders|November 17, 2017
Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 yearsFred D Lublin, Stacey S Cofield, Gary R Cutter, et al.
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|January 1, 1997
Clinical and magnetic resonance imaging changes correlate in a clinical trial monitoring cyclosporine therapy for multiple sclerosis. The MS Study GroupG J Zhao, D K Li, J S Wolinsky, et al.
Annals of Neurology|May 1, 1977
Adenine arabinoside in the treatment of progressive multifocal leukoencephalopathy: use of virus-containing cells in the urine to assess response to therapyK H Rand, K P Johnson, L J Rubinstein, et al.
Annals of Neurology|February 21, 2013
Randomized study combining interferon and glatiramer acetate in multiple sclerosisFred D Lublin, Stacey S Cofield, Gary R Cutter, et al.
Journal of Magnetic Resonance Imaging : JMRI|November 26, 2013
Contrast enhanced MR venography with gadofosveset trisodium: evaluation of the intracranial and extracranial venous systemLarry A Kramer, Alan M Cohen, Khader M Hasan, et al.
Neurology|September 3, 2021
Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple SclerosisStephen L Hauser, Ludwig Kappos, Xavier Montalban, et al.
JAMA Neurology|June 9, 2020
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical TrialsLudwig Kappos, Jerry S Wolinsky, Gavin Giovannoni, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 12, 2021
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trialBianca Weinstock-Guttman, Robert Bermel, Gary Cutter, et al.
Pageof 34